Replies to post #278574 on Anavex Life Sciences Corp (AVXL)

[vg_future]

Follow the chain and see the bias. Possibility of bad data....bad data is as important as good for scientific community......are you kidding me.....Misslling wants to show the scientific community “what not to do” in a LB session that is requested after the deadline and after claiming significant improvements in a PR and....wait wait....By presenting PDD study data in a Alzheimers conference. That is a stretch for realism.

vg_future

[Steady_T]

I'm sure you are correct about presenting bad results. However... In this case there are several things mitigating against that theory.

First of all, most trials that present bad data are high profile trials from big companies. Anavex trial is neither. Remember that Anavex is a footnote in the pharma world at this point.

Secondly, Anavex could well present negative data and it seems unlikely that Anavex would do that in one of the highest profile conferences in the world.

Thirdly, It seems unlikely that the most prestigious AD conference would choose to present a failing PDD trial as that would have little relevance to the AD audience.

That footnote categorization is about to change methinks.

[McMagyar]

I come not to bury Caesar but to praise him.
Short sellers would make posts questioning Dr M and Dr Aasland’s words of Stat Sig.
Then say .. not questioning them,, just saying..
out